Sepracor Sales Force Expansion To 1,900 Planned For Up To 10 New Products
Executive Summary
Sepracor plans to add more than 1,700 sales reps in the next three years to support upcoming product launches, President and COO William O'Shea announced during a Dec. 4 analyst conference.
You may also be interested in...
Sepracor Estorra
Brand name Estorra for sleep disorders treatment esopiclone selected by Sepracor. An NDA for Estorra, the single isomer version of Aventis' Imovane (zopiclone), is expected by the end of 2001. Sepracor plans to have 1,250 reps in place for a scheduled 2002 launch (1"The Pink Sheet" Dec. 11, 2000, p. 24)
Sepracor Estorra
Brand name Estorra for sleep disorders treatment esopiclone selected by Sepracor. An NDA for Estorra, the single isomer version of Aventis' Imovane (zopiclone), is expected by the end of 2001. Sepracor plans to have 1,250 reps in place for a scheduled 2002 launch (1"The Pink Sheet" Dec. 11, 2000, p. 24)
Lilly, Sepracor Pursue Non-Selective Antidepressants; (R)-Fluoxetine Dropped
Lilly's termination of (R)-fluoxetine commits the company to developing non-selective agents to continue its presence in the antidepressant market.